VivoSeq
Other

Cervicitis

3

Pipeline Programs

0

Active Trials

2

Companies Involved

Cervicitis is an early-stage landscape with 3 programs across 2 companies. The most active players are Pfizer, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 2 programs are in Phase 3.

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

0/100

Attrition Rate

50/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Trial Status

2

clinical trials

Terminated1 · 50%
Unknown status1 · 50%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)